Your search history is turned on.
Date: May 8, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario, Quebec
IntelGenx Announces Voting Results on Election of Directors SAINT LAURENT, Quebec, May 08, 2024 -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the Company or IntelGenx) announces that, at the annual meeting of shareholders of the Company held on May 7, 2024 (the Annual Meeting), shareholders voted in favour of all items of business put forth by the Company, including the election of the d...
Date: April 16, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, North West Territories, Nunavut, Ontario, Price Edward Island, Saskatchewan, Yukon
20240416_Updated_Cdn_OM UPDATED* CANADIAN OFFERING MEMORANDUM February 20, 2024 as updated April 16, 2024 The Issuer Name: IntelGenx Technologies Corp. (the Company) Head office: Address: 6420 Abrams, Ville Saint-Laurent, Qubec, H4S 1Y2 Phone #: (514) 331-7440 E-mail address: [email protected] Fax...
Date: April 8, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario, Quebec
IntelGenx Announces First Parkinsons Disease Patients Dosed with Montelukast VersaFilm in Phase 2 MONTPARK Clinical Trial SAINT LAURENT, Quebec, April 08, 2024 -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm has been administered to the first Parkinsons Disease (PD) patients in the Phase 2 (MONTPARK) clinical trial. MONTPARK ...
Date: April 5, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario, Quebec
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA SAINT LAURENT, Quebec, April 05, 2024 -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the Company or IntelGenx) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (Xiromed), has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its resubmitte...
Date: March 21, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario, Quebec
IntelGenx Technologies Corp.: Exhibit 23.1 - Filed by newsfilecorp.com Exhibit 31.2 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Andre Godin, certify that: 1. I have reviewed this Annual Report on Form 10-K of IntelGenx Technologies Corp. for the year ended December 31, 2023; 2. Based on my knowledge, this report does not contain an...
IntelGenx Technologies Corp.: Exhibit 23.1 - Filed by newsfilecorp.com Exhibit 31.1 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dwight Gorham, certify that: 1. I have reviewed this Annual Report on Form 10-K of IntelGenx Technologies Corp. for the year ended December 31, 2023; 2. Based on my knowledge, this report does not contain ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 00...
Date: March 21, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, ZERBE, Ingrid, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable...